Adverum Biotechnologies and Editas Medicine Extend Research Collaboration
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. “Our collaboration with Editas is focused on utilizing our next-generation adeno-associated viral (AAV) vectors to deliver Editas’ CRISPR-based genome editing technologies to develop novel therapies for debilitating eye diseases,” said Amber Salzman, Ph.D., President and Chief Executive Officer, Adverum Biotechnologies. “Extending our collaboration validates the important work underway to use our next-generation vectors.” “This collaborative work brings together our best-in-class genome editing platform and Adverum’s industry-leading
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Mizuho from $40.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingGlobeNewswire
- Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
ADVM
Earnings
- 11/9/23 - Miss
ADVM
Sec Filings
- 4/29/24 - Form SC
- 4/1/24 - Form EFFECT
- 3/27/24 - Form EFFECT
- ADVM's page on the SEC website